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abortions in horses. BUNV includes 27 strains / isolates with ac-
tivity around the world. In the US, Panama, Colombia and Guyana
it is documented the pathogenic potential of BUNV in both ani-
mals and humans because the infection by this virus was found
associated with the production of Central Nervous System dis-
ease, congenital malformations and abortions. In Argentina, two
strains of BUNV have been recovered frommosquitoes, (1) CbaAr-
426 (Cordoba, 1964/1965), and (2) AG83-1746 (Santa Fe, 1981).
Serological surveys have detected high prevalence of BUNV
infection in humans (healthy and undifferentiated febrile syn-
drome and neurological) as well as in domestic and wild life
animals but only febrile diseases have been reported in humans
infected by BUNV. During the autumn of 2013 in of Santa Fe
province, took place the ﬁrst outbreak by BUNV in the country,
during which occurred the death of two horses with neurological
syndrome from which 2 new strains of BUNV (SFCrEq231 and
SFBzEq232) were isolated; later (July, 2013) in the same area
another BUNV strain (SFAbCrEq238) was recovered from the
brain of an equine abortion. Serologic records in cohabiting
horses in Santa Fe province indicate a seroprevalence over 50%
(strain CbaAr-426). Genomic ampliﬁcation and the subsequent
phylogenetic analysis of a 250 bp of segment S the 3 new strains
showed 100% homology between them and 98,9% with the strain
CbaAr426 isolated in Cordoba which although is responsible for
high seroprevalence in domestic and wild life animals has not
been found associated with disease production. Moreover the
phylogenetic analysis of the complete genome of the new strains
with the other strains of BUNV available in Genbank showed a
homology of 99,4 % with strain 86MSP18 (isolated from a human
with febrile syndrome in Panama in 1985) for the Segment S. For
this ﬁnal phylogenetic analysis, the strain CbaAr426 It was not
included because the whole genome sequence is not available.
These ﬁndings highlight the circulation of new strains of BUNV in
Argentina and constitute the ﬁrst evidence of a possible associa-
tion between infection by BUNV and neurological syndrome in
domestic animals for our country. Moreover, these results un-
derline the importance of intensifying the surveillance of BUNV to
determine its likely real impact and to improve differential
diagnosis.
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Equine Protozoal Myeloencephalitis (EPM) is a serious neurologic
disease in equids. Although seroprevalence has been reported to
be high in horses, the actual prevalence of disease has been
estimated between 0.5 to 1%, based on laboratory submission to
the University of Kentucky. However, incidence (number of new
diagnosed cases) of EPM in horses has not been reported. The
purpose of this studywas to determine the incidence and breed of
EPM cases in equids presented to Veterinary Teaching Hospitals
(VTH) in North America and to determine if the incidence of EPM
was decreasing over time. A secondary purpose of the study was
to survey veterinary practitioners to determine if they perceive
that the incidence of EPM is decreasing over time. Equine acces-
sions reported to the Veterinary Medical Data Base (VMDB) from
1990-2014 were used for this study. Medical records from theVMDB (Systematized Nomenclature of Medicine [SNOMED] and
Systematized Nomenclature of Veterinary Diseases and Opera-
tions [SNVDO]) were accessed for overall EPM proportional
morbidity rates (PMR), PMR by database, PMR compared by
breed, and annual PMR from 1990-2014. Also, results of an on-line
survey questionnaire (Zoomerang.com) were summarized. The
on-line survey, containing 12 questions, was completed by equine
practitioners who were members of either the Equine Clinicians
Network (ECN) or the American Association of Equine Practi-
tioners (AAEP) list-serves. There were 2,748 cases of EPM per
312,222 accessions resulting in an overall PMR of 0.88%, among
hospitals reporting to the VMDB during the study period. The
PMR was not signiﬁcantly different between the two databases
(SNOMED and SNOVDO). Proportional diagnoses increased from
0.293% in 1990 to 1.952% in 1997, which was a signiﬁcantly
(P<0.05) higher than the overall PMR (0.88%). Although, there
was a signiﬁcant increase in the PMR of EPM cases from 1995-
1998, there was no evidence of a signiﬁcant temporal increase
over the 24-year study period. The PMRs were signiﬁcantly
(P<0.05) higher in Standardbreds (1.592%), Walking Horses
(1.367%), Thoroughbreds (1.314%), andWarmbloods (1.096%) than
all breeds combined (0.88%). However, the PMRs were signiﬁ-
cantly (P<0.05) lower in Draft breeds (0.518%), Ponies (0.591%),
and Quarter Horses (0.694%), when compared to the PMR for all
breeds. For the survey, there were 221 respondents and 153 (69%)
were from private practice and 68 (31%) were from academia. The
average number of practitioners per practice was 8. Thirty-eight
percent of the equine practitioners perceived that it had not
changed over the previous 2-4 years. Our ﬁndings seem to sug-
gest breed predispositions, with higher PMRs being observed in
Standardbreds, Walking Horses, and Thoroughbreds and lower
PMRs being observed in Draft breeds, ponies and Quarter Horses.
The majority of practitioners surveyed thought that the incidence
of EPM had either not changed or decreased in the previous 2-4
years. Although there was a signiﬁcant increase in EPM case
diagnosed from 1995-1997, it appears from these data that the
overall proportion of EPM cases has essentially not changed over
the past 24 years.
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Latent infections are the cornerstone of EHV-1’s continued suc-
cess. Consequently, EHV-1, unlike equine inﬂuenza and even
strangles (S. equi) is not an infection that can be practically
eradicated from equine populations. Conﬁrmation and contain-
ment of EHV-1 outbreaks is necessary to avoid spread of infection
and to minimise the potential for signiﬁcant impact to the equine
industry frommorewidespread outbreaks, in particular, large and
widely disseminated outbreaks of EHV-1 neurological disease. In
recent years, experience gained through management of EHV-1
neurological disease outbreaks in the United Kingdom (UK) has
led to establishment of protocols to control the spread of disease
and minimise equine industry losses. To that end the Animal
Health Trust, working with the UK equine industry, has proposed
three possible tiers of approach as to how EHV-1 neurological
outbreaks can be practically managed. The three tiers of approach
are referred to as Gold, Silver and Bronze and whilst they are all
based on the same set of principles of Segregation of the popula-
tion, Collection and Testing of samples and Observation of clinical
Table 1
Vaccination schedule
Group # of
horses
1st vaccination
Week 0
2nd vaccination
Week 2
3rd vaccination
Week 6
1 3 1ml Vetera®
Gold + VEE
N/A N/A
2 3 0.2mg DIII 0.2mg DIII 0.2mg DIII
3 3 0.2mg DIII+T 0.2mg DIII+T 0.2mg DIII
4 3 0.2mg DIII-
CD40L
0.2mg DIII-
CD40L
0.2mg DIII-CD40L
5 3 0.2mg DIII-
CD40L+T
0.2mg DIII-
CD40L+T
0.2mg DIII-CD40L
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strength of evidence accrued, the time required and the costs
incurred. Segregation into smaller discrete groups is common to
all three approaches and is believed to be key to a successful
strategy through minimising the spread of disease through the
population and allowing clearance and release of quarantine
measures as soon as possible. The Gold tier option provides
insight into both the extent of recent infectious spread (based on
CFT serology) and current infectiousness (based on agent detec-
tion tests, especially PCR) in each segregated group while allow-
ing risk management to then be optimised speciﬁcally to each
group. This option also facilitates prompt removal to an isolation
area of infectious horses from segregated groups, so reducing
likelihood of ongoing infectious transmission within the group
and overall morbidity. The Silver tier option incurs fewer costs
than the Gold option as whole blood samples are not screened for
viraemia by virus isolation (qPCR is not optimised for this pur-
pose), but it only provides an insight into the extent of actively
shedding and exposed horses without detecting potentially in-
fectious viraemic animals. The Bronze tier option provides a
retrospective insight into the extent of infectious spread but relies
on observation of neurological signs and/or abortions/neonatal
foal deaths to trigger further investigations, thereby potentially
missing subclinical infectious spread, which is a recognised
phenomenon in propagating EHV-1 outbreaks. This option may
be the cheapest of the three with respect to laboratory costs but
the lack of initial information about the infectious status in all
segregated groups might ultimately lengthen the time for
effecting overall control of the outbreak and depending on how
many segregated groups are further investigated, may ultimately
not signiﬁcantly reduce laboratory costs.
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WestNile Virus (WNV), since its introduction in 1999, is endemic in
the US and causes severe neurologic disease in horses. There is no
effective pharmaceutical treatment for WNV infection, so vaccina-
tion is the only approach to prevention and control of disease. The
purpose of this study was to evaluate a recombinant vaccine con-
taining Domain III (DIII) of the WNV envelope glycoprotein with
and without a natural adjuvant CD-40L in producing virus
neutralizing antibodies in horses. Fifteen Thoroughbred horses
were randomly divided into ﬁve groups and were immunized per
the schedule in Table 1. Venous blood samples were collected from
each horse prior to vaccination, the 1 and 2 weeks after initial
vaccination, and biweekly thereafter to 16 weeks. Serum IgGa
concentration in horses vaccinated with the DIII-CD40L+TiterMax
and DIII-CD40L groups were increased after the second booster
vaccination and were signiﬁcantly (p<0.05) higher compared to
other groups. Serum IgGb and IgG(T) concentrations were not
signiﬁcantly increased during the experimental period among all
groups. Western blot results showed that DIII-CD40L protein (with
or without TiterMax) groups had the highest speciﬁc anti-DIII
antibody activities after vaccinations. Moreover, the groups
immunized with DIII-CD40L protein (with or without TiterMax)
showed stronger neutralization activity and were signiﬁcantly(p<0.05) higher compared to other groups starting from Week 8.
The results demonstrated that vaccinationwith recombinantWNV
E DIII-CD40L protein induced speciﬁc immune response in healthy
horses that might be protective against WNV-associated disease.
CD40L couldbeutilizedas anon-toxic, alternative adjuvant toboost
the immunogenicity of subunit vaccines in horses.T: TiterMax adjuvant was purchased from CytRx Corporation.
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Vaccination of domestic animal against rabies is important for
preventing this fatal infection, which in turn reduces the risk of
human exposure in rabies-endemic areas. These public health
concerns provided the main impetus for the American Associa-
tion of Equine Practitioners (AAEP) to include rabies as a core
vaccine for all horses in North America in its vaccination guide-
lines. The result is that a higher proportion of horses, including
broodmares, are now rabies antibody-positive, as are their foals
via passive transfer of maternally derived antibodies (MDA).
Current label recommendations for primary vaccination against
rabies include administration of one dose of inactivated vaccine at
three months of age or older, followed by a second dose at one
year of age. MDA has been shown to inhibit the response of three-
month-old foals to inactivated vaccines directed against several
important equine pathogens; however, the impact of MDA on the
response of foals to rabies vaccine has not previously being
investigated. The serologic response to two doses of an inacti-
vated rabies vaccine administered onemonth apart was evaluated
using the rapid ﬂorescent focus inhibition test (RFFIT) in three-
month-old and six-month-old foals born to rabies-vaccinated
mares. Foals from non-vaccinated mares served as antibody-
negative controls. Rabies antibodies were not detected in samples
collected before vaccination from foals born to non-vaccinated
mares. In contrast, high titers of antibody were present in post-
nursing samples from foals born to vaccinated mares. Titers
declined with a half-life of approximately 30 days; however,
rabies antibody was still detectable at six months of age in most
foals. Both three-month-old and six-month-old foals from non-
vaccinated mares mounted a substantial serolologic response
after administration of one dose of vaccine, and experienced a
further increase in titer after administration of the second dose
four weeks later. In contrast, MDAs present at the time of initial
vaccination completely blocked the response of three-month-old
foals from vaccinated mares to administration of two doses of
vaccine. The response of these foals to a third dose administered
at one year of age was much poorer than the response seen in
